It ain’t over ‘til it’s over
- 16 November 2020 (5 min read)
Key points
- The sanitary situation in the US is concerning and the good news on the vaccine won’t likely change the macro trajectory before mid-2021. In the meantime, policy-makers will be under heightened pressure. The ECB is moving towards implicit yield control but in some EMs the room for accommodation has disappeared. It would be nice to get some closure on the Brexit saga, but the negotiations may have to spill over next week.
After the near-exclusive focus on the US elections, attention has returned to the sanitary situation. News on this front are not positive in the US, pointing at more severe restriction to activity in the weeks ahead. This, together with the continuation of the lockdowns in many European countries, suggests that the good news on a vaccine will not alter the trajectory of GDP growth in most developed nations before mid-2021.
During the first wave in the US Democrats and Republicans had managed to bridge their difference and come up with a huge fiscal stimulus. So far in this second wave, no progress has been done. We are convinced help will come, but more in a reactive than in a pre-emptive way, and probably with less magnitude.
Meanwhile, in Europe the ECB is becoming ever clearer on its pandemic-fighting strategy. Christine Lagarde speech at the central bank’s annual conference contained more than a hint at implicit yield control. With its insistence on fighting “crowding out”, the ECB sent the signal it would effectively cap sovereign interest rates even when the supply of sovereign paper rises to make space for the fiscal stimulus. This implies that it will need all the flexibility of the PEPP – which we expect to see extended in December - to achieve this.
But policy accommodation is no longer possible everywhere. The market expects a huge rate hike in Turkey this week (marginally south of 500 basis points, on top of the 200 basis points delivered in September). Their situation is significantly less problematic than Turkey’s but India and to a lesser extent Mexico are also dealing with a resurgence in inflation which will impair their capacity to provide additional stimulus. This is not necessarily conducive to systemic crises in EM (in most cases –Turkey being a major exception - their international financial position is solid) but is an issue for global demand in this second wave.
This week is expected to bring closure on the “Brexit saga” but negotiations may have to continue into next week. We don’t think the dismissal of two leading “Vote Leave” advisors from the Prime Minister’s office necessarily reflects a change of stance on this issue from Boris Johnson. He still needs some concessions to sell the agreement to the most radical wing of his party. We remain optimistic, but it will be a tense game until the very end.
Not for Retail distribution
This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.
It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date.
All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document. Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.
Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.